Bristol Myers Squibb and 2seventy bio published positive results Friday from a pivotal trial of their B-cell maturation antigen–directed (BCMA) CAR T-cell therapy in multiple myeloma patients who had received two to four prior lines of therapy.
The company is testing Carvykti in multiple myeloma patients, with a history of relapse, who have stopped responding to existing treatment and have received one to three prior therapies.
The company had said this month that Blenrep failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the FDA.
The company announced that its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market.
Thermo Fisher Scientific Inc said it would buy Binding Site Group from European private equity firm Nordic Capital in an all-cash transaction valued at 2.25 billion pounds ($2.6 billion), boosting its specialty diagnostics business.
The therapy Tecvayli is a bispecific antibody, which is engineered to redirect body’s immune system to recognize and kill cancer cells. It is the first drug of its class to be approved for multiple myeloma.
With Celgene and other acquisition costs in the rearview, Bristol Myers Squibb returned to profitability with a vengeance in 2021.
Biohaven Pharmaceuticals has set a new course following its acquisition by Pfizer with a focus on developing therapeutics that modulate the Kv7 ion channel for the treatment of neurological and neuropsychiatric diseases.
Elevation Oncology, Janssen, Merck and Teclison discuss the latest innovations in immuno-oncology.
Two months after Janssen won a ruling in arbitration over the licensing and marketing of the multiple myeloma drug Darzalex Faspro (daratumumab), Genmab A/S is seeking a new arbitration ruling granted under its license with the larger pharmaceutical company.